[1] |
HALBROOK CJ, LYSSIOTIS CA, PASCA DI MAGLIANO M, et al. Pancreatic cancer: Advances and challenges[J]. Cell, 2023, 186( 8): 1729- 1754. DOI: 10.1016/j.cell.2023.02.014.
|
[2] |
GAIANIGO N, MELISI D, CARBONE C. EMT and treatment resistance in pancreatic cancer[J]. Cancers, 2017, 9( 9): 122. DOI: 10.3390/cancers9090122.
|
[3] |
FRIEND C, PARAJULI P, RAZZAQUE MS, et al. Deciphering epithelial-to-mesenchymal transition in pancreatic cancer[J]. Adv Cancer Res, 2023, 159: 37- 73. DOI: 10.1016/bs.acr.2023.02.008.
|
[4] |
KECHAGIA Z, SÁEZ P, GÓMEZ-GONZÁLEZ M, et al. The laminin-keratin link shields the nucleus from mechanical deformation and signalling[J]. Nat Mater, 2023, 22( 11): 1409- 1420. DOI: 10.1038/s41563-023-01657-3.
|
[5] |
TAYEM R, NIEMANN C, PESCH M, et al. Laminin 332 is indispensable for homeostatic epidermal differentiation programs[J]. J Invest Dermatol, 2021, 141( 11): 2602- 2610. e 3. DOI: 10.1016/j.jid.2021.04.008.
|
[6] |
O’CONNELL P. Of LAMA3 and LAMB3: A novel gene therapy for epidermolysis bullosa[J]. Mol Ther, 2024, 32( 5): 1197- 1198. DOI: 10.1016/j.ymthe.2024.04.014.
|
[7] |
YAMASHITA H, TRIPATHI M, HARRIS MP, et al. The role of a recombinant fragment of laminin-332 in integrin alpha3beta1-dependent cell binding, spreading and migration[J]. Biomaterials, 2010, 31( 19): 5110- 5121. DOI: 10.1016/j.biomaterials.2010.03.003.
|
[8] |
ZENZO GD, HACHEM ME, DIOCIAIUTI A, et al. A truncating mutation in the laminin-332α chain highlights the role of the LG45 proteolytic domain in regulating keratinocyte adhesion and migration[J]. Br J Dermatol, 2014, 170( 5): 1056- 1064. DOI: 10.1111/bjd.12816.
|
[9] |
TOMCZAK K, CZERWIŃSKA P, WIZNEROWICZ M. The Cancer Genome Atlas(TCGA): An immeasurable source of knowledge[J]. Contemp Oncol, 2015, 19( 1A): A68- A77. DOI: 10.5114/wo.2014.47136.
|
[10] |
SUBRAMANIAN A, TAMAYO P, MOOTHA VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles[J]. Proc Natl Acad Sci U S A, 2005, 102( 43): 15545- 15550. DOI: 10.1073/pnas.0506580102.
|
[11] |
CARITHERS LJ, MOORE HM. The genotype-tissue expression(GTEx) project[J]. Biopreserv Biobank, 2015, 13( 5): 307- 308. DOI: 10.1089/bio.2015.29031.hmm.
|
[12] |
BARRETT T, WILHITE SE, LEDOUX P, et al. NCBI GEO: Archive for functional genomics data sets: Update[J]. Nucleic Acids Res, 2013, 41( Database issue): D991- D995. DOI: 10.1093/nar/gks1193.
|
[13] |
UHLEN M, ZHANG C, LEE S, et al. A pathology atlas of the human cancer transcriptome[J]. Science, 2017, 357( 6352): eaan2507. DOI: 10.1126/science.aan2507.
|
[14] |
HUANG CQ, CHEN J. Laminin-332 mediates proliferation, apoptosis, invasion, migration and epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma[J]. Mol Med Rep, 2021, 23( 1): 11. DOI: 10.3892/mmr.2020.11649.
|
[15] |
TRAUB B, LINK KH, KORNMANN M. Curing pancreatic cancer[J]. Semin Cancer Biol, 2021, 76: 232- 246. DOI: 10.1016/j.semcancer.2021.05.030.
|
[16] |
PARK W, CHAWLA A, O’REILLY EM. Pancreatic cancer: A review[J]. JAMA, 2021, 326( 9): 851- 862. DOI: 10.1001/jama.2021.13027.
|
[17] |
DERYNCK R, WEINBERG RA. EMT and cancer: More than meets the eye[J]. Dev Cell, 2019, 49( 3): 313- 316. DOI: 10.1016/j.devcel.2019.04.026.
|
[18] |
PALAMARIS K, FELEKOURAS E, SAKELLARIOU S. Epithelial to mesenchymal transition: Key regulator of pancreatic ductal adenocarcinoma progression and chemoresistance[J]. Cancers, 2021, 13( 21): 5532. DOI: 10.3390/cancers13215532.
|
[19] |
SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66( 1): 7- 30. DOI: 10.3322/caac.21332.
|
[20] |
LI DD, XIA LY, HUANG P, et al. Heterogeneity and plasticity of epithelial-mesenchymal transition(EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms[J]. Cell Prolif, 2023, 56( 6): e13423. DOI: 10.1111/cpr.13423.
|
[21] |
REN H, DU PZ, GE ZY, et al. TWIST1 and BMI1 in cancer metastasis and chemoresistance[J]. J Cancer, 2016, 7( 9): 1074- 1080. DOI: 10.7150/jca.14031.
|
[22] |
PAUL MC, SCHNEEWEIS C, FALCOMATÀ C, et al. Non-canonical functions of SNAIL drive context-specific cancer progression[J]. Nat Commun, 2023, 14( 1): 1201. DOI: 10.1038/s41467-023-36505-0.
|
[23] |
WEI T, ZHANG XY, ZHANG Q, et al. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer[J]. Cancer Lett, 2019, 452: 237- 243. DOI: 10.1016/j.canlet.2019.03.009.
|
[24] |
MALTSEVA DV, RODIN SA. Laminins in metastatic cancer[J]. Mol Biol, 2018, 52( 3): 411- 434. DOI: 10.7868/S0026898418030059.
|
[25] |
ROUSSELLE P, SCOAZEC JY. Laminin 332 in cancer: When the extracellular matrix turns signals from cell anchorage to cell movement[J]. Semin Cancer Biol, 2020, 62: 149- 165. DOI: 10.1016/j.semcancer.2019.09.026.
|
[26] |
NING BS, MEI YE. LAMA3 promotes tumorigenesis of oral squamous cell carcinoma by METTL3-mediated N6-methyladenosine modification[J]. Crit Rev Immunol, 2024, 44( 2): 49- 59. DOI: 10.1615/CritRevImmunol.2023051066.
|
[27] |
ISLAM K, BALASUBRAMANIAN B, VENKATRAMAN S, et al. Upregulated LAMA3 modulates proliferation, adhesion, migration and epithelial-to-mesenchymal transition of cholangiocarcinoma cells[J]. Sci Rep, 2023, 13( 1): 22598. DOI: 10.1038/s41598-023-48798-8.
|
[28] |
FENG LY, HUANG YZ, ZHANG W, et al. LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer[J]. J Ovarian Res, 2021, 14( 1): 67. DOI: 10.1186/s13048-021-00807-y.
|